149 related articles for article (PubMed ID: 38015774)
41. Estimating life expectancy adjusted by self-rated health status in the United States: national health interview survey linked to the mortality.
Cho H; Wang Z; Yabroff KR; Liu B; McNeel T; Feuer EJ; Mariotto AB
BMC Public Health; 2022 Jan; 22(1):141. PubMed ID: 35057780
[TBL] [Abstract][Full Text] [Related]
42. Cancer screening rates in individuals with different life expectancies.
Royce TJ; Hendrix LH; Stokes WA; Allen IM; Chen RC
JAMA Intern Med; 2014 Oct; 174(10):1558-65. PubMed ID: 25133746
[TBL] [Abstract][Full Text] [Related]
43. Measuring the impact of HIV/AIDS, heart disease and malignant neoplasms on life expectancy in the USA from 1987 to 2000.
Lai DJ; Tarwater PM; Hardy RJ
Public Health; 2006 Jun; 120(6):486-92. PubMed ID: 16730037
[TBL] [Abstract][Full Text] [Related]
44. Trends in life expectancy: did the gap between the healthy and the ill widen or close?
Meyer AC; Drefahl S; Ahlbom A; Lambe M; Modig K
BMC Med; 2020 Mar; 18(1):41. PubMed ID: 32192480
[TBL] [Abstract][Full Text] [Related]
45. Influence of Age, Health, and Function on Cancer Screening in Older Adults with Limited Life Expectancy.
Schoenborn NL; Huang J; Sheehan OC; Wolff JL; Roth DL; Boyd CM
J Gen Intern Med; 2019 Jan; 34(1):110-117. PubMed ID: 30402822
[TBL] [Abstract][Full Text] [Related]
46. Cancer survival statistics for patients and healthcare professionals - a tutorial of real-world data analysis.
Eloranta S; Smedby KE; Dickman PW; Andersson TM
J Intern Med; 2021 Jan; 289(1):12-28. PubMed ID: 32656940
[TBL] [Abstract][Full Text] [Related]
47. Cancer screening and life expectancy of Canadian patients with kidney failure.
Kajbaf S; Nichol G; Zimmerman D
Nephrol Dial Transplant; 2002 Oct; 17(10):1786-9. PubMed ID: 12270985
[TBL] [Abstract][Full Text] [Related]
48. Health-related quality of life of patients with resistant/intolerant chronic phase chronic myeloid leukemia treated with asciminib or bosutinib in the phase 3 ASCEMBL trial.
Réa D; Boquimpani C; Mauro MJ; Minami Y; Allepuz A; Maheshwari VK; D'Alessio D; Wu Y; Lawrance R; Narbutas S; Sharf G; Hochhaus A
Leukemia; 2023 May; 37(5):1060-1067. PubMed ID: 37069326
[TBL] [Abstract][Full Text] [Related]
49. 37-year incidence and mortality time trends of common cancer types by sex, age, and stage in the canton of Zurich.
Wanner M; Matthes KL; Karavasiloglou N; Limam M; Korol D; Rohrmann S
Swiss Med Wkly; 2020 Dec; 150():w20388. PubMed ID: 33378540
[TBL] [Abstract][Full Text] [Related]
50. Life expectancy after curative-intent treatment of breast cancer: impact on long-term follow-up care.
Arrington AK; Goldstein L; Kruper L; Vito C; Yim J; Chen SL
Am Surg; 2014 Jun; 80(6):604-9. PubMed ID: 24887800
[TBL] [Abstract][Full Text] [Related]
51. Life expectancy and cancer survival in Oncosalud: outcomes over a 15-year period in a Peruvian private institution.
Colonio C; Lecman L; Pinto JA; Vallejos C; Pinillos L
Ecancermedicalscience; 2021; 15():1336. PubMed ID: 35211205
[TBL] [Abstract][Full Text] [Related]
52. Geographic Disparity of Outcome in Patients With Cancer Over Decades: The Surveillance, Epidemiology, and End Results.
Sasaki K; Morita K; Kantarjian H; Garcia-Manero G; Jabbour E; Ravandi F; Konopleva M; Borthakur G; Wierda W; Daver N; Takahashi K; DiNardo C; Bravo GM; Issa GC; Pierce SA; Soltysiak KA; Tingen MS; Cortes JE
Clin Lymphoma Myeloma Leuk; 2023 Nov; 23(11):e369-e378. PubMed ID: 37690903
[TBL] [Abstract][Full Text] [Related]
53. Chronic myeloid leukemia as a secondary malignancy after lymphoma in a child. A case report and review of the literature.
Zahra K; Ben Fredj W; Ben Youssef Y; Zaghouani H; Chebchoub I; Zaier M; Badreddine S; Braham N; Sennana H; Khelif A
Onkologie; 2012; 35(11):690-3. PubMed ID: 23147546
[TBL] [Abstract][Full Text] [Related]
54. The option value of innovative treatments in the context of chronic myeloid leukemia.
Sanchez Y; Penrod JR; Qiu XL; Romley J; Thornton Snider J; Philipson T
Am J Manag Care; 2012 Nov; 18(11 Suppl):S265-71. PubMed ID: 23327458
[TBL] [Abstract][Full Text] [Related]
55. Population-Based Testing and Treatment Characteristics for Chronic Myelogenous Leukemia.
Styles T; Wu M; Wilson R; Babcock F; Butterworth D; West DW; Richardson LC
J Registry Manag; 2016; 41(3):134-142. PubMed ID: 28121314
[TBL] [Abstract][Full Text] [Related]
56. The contribution of cancer incidence, stage at diagnosis and survival to racial differences in years of life expectancy.
Wong MD; Ettner SL; Boscardin WJ; Shapiro MF
J Gen Intern Med; 2009 Apr; 24(4):475-81. PubMed ID: 19189193
[TBL] [Abstract][Full Text] [Related]
57. Life expectancy as a measurement of the benefit shown by clinical trials of treatment for early breast cancer.
Haybittle JL
Clin Oncol (R Coll Radiol); 1998; 10(2):92-4. PubMed ID: 9610897
[TBL] [Abstract][Full Text] [Related]
58. Cancer cure for 32 cancer types: results from the EUROCARE-5 study.
Dal Maso L; Panato C; Tavilla A; Guzzinati S; Serraino D; Mallone S; Botta L; Boussari O; Capocaccia R; Colonna M; Crocetti E; Dumas A; Dyba T; Franceschi S; Gatta G; Gigli A; Giusti F; Jooste V; Minicozzi P; Neamtiu L; Romain G; Zorzi M; De Angelis R; Francisci S;
Int J Epidemiol; 2020 Oct; 49(5):1517-1525. PubMed ID: 32984907
[TBL] [Abstract][Full Text] [Related]
59. BCR-ABL-mediated upregulation of PRAME is responsible for knocking down TRAIL in CML patients.
De Carvalho DD; Binato R; Pereira WO; Leroy JM; Colassanti MD; Proto-Siqueira R; Bueno-Da-Silva AE; Zago MA; Zanichelli MA; Abdelhay E; Castro FA; Jacysyn JF; Amarante-Mendes GP
Oncogene; 2011 Jan; 30(2):223-33. PubMed ID: 20838376
[TBL] [Abstract][Full Text] [Related]
60. Using healthcare claims data to analyze the prevalence of BCR-ABL-positive chronic myeloid leukemia in France: A nationwide population-based study.
Foulon S; Cony-Makhoul P; Guerci-Bresler A; Delord M; Solary E; Monnereau A; Bonastre J; Tubert-Bitter P
Cancer Med; 2019 Jun; 8(6):3296-3304. PubMed ID: 31038849
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
